News
Wegovy (semaglutide) will no longer be available through Hims & Hers Health, as Novo Nordisk has ended its short-lived partnership.
Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.
Just two days after Novo Nordisk launched Wegovy (semaglutide 2.4 mg) in India, Eli Lilly received regulatory approval for ...
Earlier this week, the pharma giant publicly accused Hims & Hers of “deceptive” marketing that is putting patient safety at risk.
Two growth stocks in the healthcare industry stand out in particular. Here is what you need to know about each one and why ...
China has approved a new weight-loss drug that is poised to rival Novo Nordisk and Eli Lilly's popular GLP-1 treatments, ...
While Novo Nordisk stock has underperformed since my Strong Buy rating four months ago, the long-term investment thesis ...
Novo Nordisk executives overlooked warnings ahead of Wegovy's launch, leading to supply issues, high costs, and challenges competing with Eli Lilly's Zepbound.
Chinese drugmaker Innogen expects to complete a late-stage clinical trial of its experimental weight-loss drug candidate next ...
GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...
Another major insurance change coming next year will affect another large swath of Dushay’s patients: In January, BCBS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results